Market Research Logo

Metastatic Pancreatic Cancer - Pipeline Review, H1 2015

Introduction
Global Markets Direct Report Coverage
Metastatic Pancreatic Cancer Overview
Therapeutics Development
Pipeline Products for Metastatic Pancreatic Cancer - Overview
Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis
Metastatic Pancreatic Cancer - Therapeutics under Development by Companies
Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes
Metastatic Pancreatic Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Metastatic Pancreatic Cancer - Products under Development by Companies
Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes
Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development
AbbVie Inc.
Aduro BioTech, Inc.
AstraZeneca PLC
AVEO Pharmaceuticals, Inc.
Axcentua Pharmaceuticals AB
Bayer AG
BioCancell Therapeutics, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Cantex Pharmaceuticals, Inc.
Celgene Corporation
Colby Pharmaceutical Company
Cornerstone Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
FibroGen, Inc.
Fountain Biopharma Inc.
Gilead Sciences, Inc.
GlaxoSmithKline plc
Halozyme Therapeutics, Inc.
Immunomedics, Inc.
Incyte Corporation
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc.
NanoCarrier Co., Ltd.
Nanotherapeutics, Inc.
NewLink Genetics Corporation
Novartis AG
Oncolytics Biotech Inc.
OncoMed Pharmaceuticals, Inc.
Oncovir, Inc.
Oncozyme Pharma Inc.
Pfizer Inc.
Pharma Mar, S.A.
Precision Biologics, Inc.
Regulon Inc.
Rexahn Pharmaceuticals, Inc.
Sanofi
Silence Therapeutics plc
Synta Pharmaceuticals Corp.
Takeda Oncology
Teva Pharmaceutical Industries Limited
Threshold Pharmaceuticals, Inc.
Metastatic Pancreatic Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Atu-027 - Drug Profile
AXP-10711 - Drug Profile
BBI-608 - Drug Profile
BC-819 - Drug Profile
bevacizumab - Drug Profile
BI-853520 - Drug Profile
binimetinib - Drug Profile
CEP-37250 - Drug Profile
CIM-1 - Drug Profile
cisplatin - Drug Profile
cisplatin liposomal - Drug Profile
clivatuzumab tetraxetan - Drug Profile
CPC-410 - Drug Profile
CPI-613 - Drug Profile
CRS-207 - Drug Profile
demcizumab - Drug Profile
Dendritic Cell Therapy for Cancer - Drug Profile
ensituximab - Drug Profile
erismodegib - Drug Profile
evofosfamide - Drug Profile
FB-704A - Drug Profile
FG-3019 - Drug Profile
ficlatuzumab - Drug Profile
galunisertib - Drug Profile
ganetespib - Drug Profile
glufosfamide - Drug Profile
indoximod - Drug Profile
irinotecan sucrosofate liposomal - Drug Profile
lapatinib ditosylate - Drug Profile
LCL-161 - Drug Profile
LGK-974 - Drug Profile
lurbinectedin - Drug Profile
LY-2109761 - Drug Profile
LY-2495655 - Drug Profile
MesoCART - Drug Profile
MK-2206 - Drug Profile
MK-2206 + selumetinib sulfate - Drug Profile
MLN-0264 - Drug Profile
necuparanib - Drug Profile
nimotuzumab - Drug Profile
olaparib - Drug Profile
paclitaxel albumin bound - Drug Profile
paclitaxel lipsomal - Drug Profile
PD-0325901 + PF-05212384 - Drug Profile
PEGPH-20 - Drug Profile
pelareorep - Drug Profile
pentamidine isethionate - Drug Profile
PGX-100 - Drug Profile
pimasertib hydrochloride - Drug Profile
plerixafor - Drug Profile
Poly-ICLC - Drug Profile
PRI-724 - Drug Profile
refametinib - Drug Profile
rottlerin - Drug Profile
ruxolitinib phosphate - Drug Profile
RX-0201 - Drug Profile
SGT-53 - Drug Profile
SiG12D-LODER - Drug Profile
simtuzumab - Drug Profile
Small Molecules to Inhibit Lysyl Oxidase for Metastatic Pancreatic Cancer - Drug Profile
Stem Cell Therapy for Oncology - Drug Profile
TL-118 - Drug Profile
trametinib dimethyl sulfoxide - Drug Profile
Triapine - Drug Profile
Vaccine to Target VEGFR-1 and VEGFR-2 for Metastatic Hepatocellular Carcinoma and Metastatic Pancreatic Cancer - Drug Profile
veliparib - Drug Profile
Metastatic Pancreatic Cancer - Recent Pipeline Updates
Metastatic Pancreatic Cancer - Dormant Projects
Metastatic Pancreatic Cancer - Discontinued Products
Metastatic Pancreatic Cancer - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Metastatic Pancreatic Cancer, H1 2015
Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2015
Metastatic Pancreatic Cancer - Pipeline by AbbVie Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by AstraZeneca PLC, H1 2015
Metastatic Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H1 2015
Metastatic Pancreatic Cancer - Pipeline by Bayer AG, H1 2015
Metastatic Pancreatic Cancer - Pipeline by BioCancell Therapeutics, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Metastatic Pancreatic Cancer - Pipeline by Boston Biomedical, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Cantex Pharmaceuticals, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Celgene Corporation, H1 2015
Metastatic Pancreatic Cancer - Pipeline by Colby Pharmaceutical Company, H1 2015
Metastatic Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Eli Lilly and Company, H1 2015
Metastatic Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Metastatic Pancreatic Cancer - Pipeline by FibroGen, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by GlaxoSmithKline plc, H1 2015
Metastatic Pancreatic Cancer - Pipeline by Halozyme Therapeutics, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Immunomedics, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Incyte Corporation, H1 2015
Metastatic Pancreatic Cancer - Pipeline by Merck & Co., Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Merck KGaA, H1 2015
Metastatic Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Nanotherapeutics, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by NewLink Genetics Corporation, H1 2015
Metastatic Pancreatic Cancer - Pipeline by Novartis AG, H1 2015
Metastatic Pancreatic Cancer - Pipeline by Oncolytics Biotech Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Oncovir, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Oncozyme Pharma Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Pfizer Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Pharma Mar, S.A., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Precision Biologics, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Regulon Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Sanofi, H1 2015
Metastatic Pancreatic Cancer - Pipeline by Silence Therapeutics plc, H1 2015
Metastatic Pancreatic Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015
Metastatic Pancreatic Cancer - Pipeline by Takeda Oncology, H1 2015
Metastatic Pancreatic Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Metastatic Pancreatic Cancer - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Metastatic Pancreatic Cancer Therapeutics - Recent Pipeline Updates, H1 2015
Metastatic Pancreatic Cancer - Dormant Projects, H1 2015
Metastatic Pancreatic Cancer - Dormant Projects (Contd..1), H1 2015
Metastatic Pancreatic Cancer - Dormant Projects (Contd..2), H1 2015
Metastatic Pancreatic Cancer - Discontinued Products, H1 2015
Metastatic Pancreatic Cancer - Discontinued Products (Contd..1), H1 2015
List of Figures
Number of Products under Development for Metastatic Pancreatic Cancer, H1 2015
Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Metastatic Pancreatic Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Metastatic Pancreatic Cancer - Pipeline Review, H1 2015’, provides an overview of the Metastatic Pancreatic Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;